Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 1000

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 9B
Chunk 1000
---
 as a director,
president & chief executive officer, moving multiple programs into clinical testing, completing several acquisitions, and eventually
taking the company public. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. (acquired by Precigen) with increasing
responsibilities, culminating as Head of Business Development. Mr. Enright brings a breadth of experiences in a variety of positions
within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc.
(acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles. Mr. Enright
received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins
University. We believe that Mr. Enright is qualified to serve as a member of our board of directors because of his extensive professional
experience in life science/biotech companies and in the management of public companies.

Jason
Hanson has served as a director and chair of the Nominating and Corporate Governance Committee since February 2023. Mr. Hanson
served as Chief Executive Officer and as a director of enGene Inc. from July 2018 to July 2024. He also served as President of enGene
Inc. from July 2018 to December 2022. Mr. Hanson effectively re-launched enGene from a small private company working in the GI discovery
space into a clinical stage gene therapy oncology company trading on Nasdaq, implementing a new scientific, technical and strategic vision
for the Company. From August 2016 to November 2017, Mr. Hanson served as President and Chief Executive Officer of Ohana Biosciences,
a biotechnology company based in Cambridge, MA, and as member of the Ohana Board of Directors and consultant to Ohana from November 2017
to June 2018. Mr. Hanson previously served as Executive Vice President and Chief Strategy Officer for NuVasive, Inc. from November 2015
to August 2016. Mr. Hanson served as Corporate Vice President of General Electric Company and member of the senior executive team of
GE Healthcare, a global pharmaceutical, medical device and healthcare services business from May 2014 to October 2015. In January 2013,
Mr. Hanson served as Company Group Chairman and Executive Vice President of Valeant Pharmaceuticals International, Inc. (now Bausch Health